SBIR/STTR Research Award
BIODEGRADABLE INJECTABLE DELIVERY SYSTEM FOR NALTREXONE
Award amount
$49,900Program and phase
SBIR · Phase IAward year
1991Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- Not reported
- Recipient company
- ATRIX LABORATORIES, INC.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Not reported
- Solicitation number
- Not reported
- Topic code
- Not reported
Research abstract
NALTREXONE IS AN EFFECTIVE NARCOTIC ANTAGONIST. HOWEVER, ITS EFFECTIVENESS IS LIMITED BY THE NEED FOR HIGH PATIENT COMPLIANCE, AS ORAL DOSAGES MUST BE TAKEN AT LEAST THREE TIMES WEEKLY. BY USING A PROPRIETARY DELIVERY SYSTEM, IT ISEXPECTED THAT NALTREXONE CAN BE DELIVERED AT A CONTROLLED RATE FOR ONE MONTH. THE DELIVERY SYSTEM TO STUDIED IS BIODEGRADABLE AND BIOCOMPATIBLE, AND HAS BEEN SHOWN TO CAUSENO ADVERSE TISSUE REACTIONS IN ANIMAL TESTING. IT HAS BEEN STUDIED IN VITRO FOR THE CONTROLLED RELEASE OF SEVERAL DRUGS AND IS CURRENTLY BEING STUDIED IN HUMANS UNDER A PHASEII IND. MOST IMPORTANTLY, IT CAN BE INJECTED USING STANDARDSYRINGES AND NEEDLES. NALTREXONE WILL BE INCORPORATED INTO THIS DELIVERY SYSTEM. THE EFFECT OF SEVERAL VARIABLES INCLUDING DRUG FORM AND POLYMER COMPOSITION, MOLECULAR WEIGHT AND CONCENTRATION, WILL BE STUDIED IN ORDER TO OBTAIN THE DESIRED RELEASE PROFILE OF 5 MG/DAY. THE MOST PROMISING FORMULATION WILL BETESTED IN RABBITS FOR TISSUE COMPATIBILITY. NALTREXONE IS AN EFFECTIVE NARCOTIC ANTAGONIST. HOWEVER, ITS EFFECTIVENESS IS LIMITED BY THE NEED FOR HIGH PATIENT COMPLIANCE, AS ORAL DOSAGES MUST BE TAKEN AT LEAST THREE TIMES WEEKLY. BY USING A PROPRIETARY DELIVERY SYSTEM, IT ISEXPECTED THAT NALTREXONE CAN BE DELIVERED AT A CONTROLLED RATE FOR ONE MONTH. THE DELIVERY SYSTEM TO STUDIED IS BIODEGRADABLE AND BIOCOMPATIBLE, AND HAS BEEN SHOWN TO CAUSENO ADVERSE TISSUE REACTIONS IN ANIMAL TESTING. IT HAS BEEN STUDIED IN VITRO FOR THE CONTROLLED RELEASE OF SEVERAL DRUGS AND IS CURRENTLY BEING STUDIED IN HUMANS UNDER A PHASEII IND. MOST IMPORTANTLY, IT CAN BE INJECTED USING STANDARDSYRINGES AND NEEDLES. NALTREXONE WILL BE INCORPORATED INTO THIS DELIVERY SYSTEM. THE EFFECT OF SEVERAL VARIABLES INCLUDING DRUG FORM AND POLYMER COMPOSITION, MOLECULAR WEIGHT AND CONCENTRATION, WILL BE STUDIED IN ORDER TO OBTAIN THE DESIRED RELEASE PROFILE OF 5 MG/DAY. THE MOST PROMISING FORMULATION WILL BETESTED IN RABBITS FOR TISSUE COMPATIBILITY.
Technology keywords
Not reported